Drug reference

Ipilimumab

Monoclonal Antibody · Antineoplastic

Also known as Yervoy

Monoclonal AntibodyAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AnisindioneSevereDatabaseDDInter
ApixabanSevereDatabaseDDInter
ArdeparinSevereDatabaseDDInter
ArgatrobanSevereDatabaseDDInter

Mechanism

Ipilimumab is a monoclonal antibody which causes T-cell activation resulting in tumour cell death. It functions as an immune checkpoint inhibitor.

Indications

Melanoma (as monotherapy) (specialist use only)Melanoma (in combination with nivolumab) (specialist use only)Advanced renal cell carcinoma (in combination with nivolumab) (specialist use only)Metastatic melanomaNon–small cell lung cancerRenal cell carcinomaHead and neck cancers (clinical trials)Breast cancer (clinical trials)Small cell lung cancer (clinical trials)Hodgkin lymphoma (clinical trials)Gastric cancer (clinical trials)Hepatocellular carcinoma (clinical trials)Bladder cancer (clinical trials)Ovarian cancer (clinical trials)Colon cancer (clinical trials)Merkel cell carcinoma (clinical trials)advanced melanoma (as a single agent or in combination with nivolumab)advanced RCC (in combination with nivolumab)colorectal cancer with high microsatellite instability (MSI-H) or mismatch repair deficient (in combination with nivolumab)pretreated hepatocellular carcinoma (in combination with nivolumab)metastatic NSCLC with no EGFR or anaplastic lymphoma kinase (ALK) genomic aberrations (in combination with nivolumab)malignant pleural mesothelioma (in combination with nivolumab)advanced melanomaneoadjuvant plus adjuvant therapy for palpable nodal disease in combination with nivolumab

Dosing

Adult: Melanoma (as monotherapy): 3 mg/kg every 3 weeks for 4 doses.

Pharmacokinetics

Half-life

15.4 days

Side effects

Common

pruritusrashvitiligodiarrheacolitisskin rashdiarrhea (sometimes severe, life-threatening colitis)

Serious

Cytomegalovirus (CMV) gastrointestinal infection or reactivation
Fatal cases of CMV gastrointestinal infection
Corticosteroid-refractory immune-related colitis
Immune-related adverse events (hepatitis, pneumonitis, colitis, rash, vitiligo, endocrine pathology)
inflammatory toxicities (73.6% of patients, 18.6% grade 3 to 4)
immune-mediated hepatitis
hypophysitis
hypo- or hyperthyroidism
myocarditis (rare, especially in combination with nivolumab)
thyroiditis
hepatitis
nephritis
pneumonitis
myocarditis
neuritis